Peripheral immunoinflammatory markers and clinical correlations in Parkinson's disease patients carrying LRRK2 G2385R and R1628P variants
En palabras de los autores
Peripheral inflammation in Parkinsons disease (PD) remains poorly characterised among carriers of Asian-prevalent LRRK2 G2385R and R1628P variants. We investigated plasma immunoinflammatory markers (i.e., IL-6, TNF-, CCL2, CX3CL1, CCL5, and VCAM-1) via multiplex immunoassay in 240 participants: PD-G2385R (n=53), PD-R1628P (n=58), PD-G2385R+R1628P (n=5), idiopathic PD (iPD; n=62), and controls (n=62), and their clinicobiological correlates including monocyte LRRK2 kinase activity (pRab10Thr73). Compared with iPD and/or controls, TNF-, CCL2, CX3CL1, and CCL5 were lower in PD-G2385R, while IL-6, TNF-, CCL2, and CCL5 were lower in PD-R1628P. Higher LRRK2 kinase activity correlated with lower TNF-. CX3CL1 correlated with greater motor severity in iPD but less disability in both variant groups. CCL5 correlated with less motor complications in PD-G2385R, while IL-6 and VCAM-1 correlated with worse disability and/or cognition in PD-R1628P. These findings suggest that immunoinflammatory profiles and their clinical relevance in PD differ by genotype, with implications for stratification in future immunomodulatory trials.
Apareció: miércoles, 23 de septiembre. medRxiv. Preprint, todavía sin revisión por pares.